Rick Bienkowski
Stock Analyst at Cantor Fitzgerald
(0.49)
# 4,138
Out of 5,044 analysts
35
Total ratings
25%
Success rate
-28.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rick Bienkowski
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Overweight | $55 | $32.57 | +68.87% | 4 | May 14, 2025 | |
| BEAM Beam Therapeutics | Reiterates: Overweight | n/a | $26.43 | - | 12 | Mar 12, 2025 | |
| ACLX Arcellx | Initiates: Overweight | n/a | $87.49 | - | 1 | Sep 3, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Overweight | $65 | $13.96 | +365.62% | 7 | Jun 24, 2024 | |
| CRBU Caribou Biosciences | Initiates: Neutral | n/a | $2.47 | - | 1 | Nov 8, 2023 | |
| EDIT Editas Medicine | Reiterates: Overweight | $14 | $3.17 | +341.64% | 6 | Sep 13, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $112 → $107 | $64.17 | +66.74% | 4 | Aug 8, 2022 |
Legend Biotech
May 14, 2025
Reiterates: Overweight
Price Target: $55
Current: $32.57
Upside: +68.87%
Beam Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.43
Upside: -
Arcellx
Sep 3, 2024
Initiates: Overweight
Price Target: n/a
Current: $87.49
Upside: -
Intellia Therapeutics
Jun 24, 2024
Reiterates: Overweight
Price Target: $65
Current: $13.96
Upside: +365.62%
Caribou Biosciences
Nov 8, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.47
Upside: -
Editas Medicine
Sep 13, 2023
Reiterates: Overweight
Price Target: $14
Current: $3.17
Upside: +341.64%
CRISPR Therapeutics AG
Aug 8, 2022
Maintains: Outperform
Price Target: $112 → $107
Current: $64.17
Upside: +66.74%